Hear Repligen's CEO give company overview at June 3 webcast
Repligen (NASDAQ: RGEN), a life sciences company, announced that its President and CEO, Olivier Loeillot, will present a company overview at the William Blair 46th Annual Growth Stock Conference on June 3 at 10:40 a.m. CT. The presentation will be available via live webcast and replay on the company's Investor Relations website. This event follows a series of recent updates including earnings, sustainability reports, and operational expansions.
APR 25·MarketBeat→
Impax Asset Management Group plc Sells 289,853 Shares of Repligen Corporation $RGEN
Impax Asset Management Group plc significantly reduced its stake in Repligen Corporation, selling 289,853 shares, which cut their holding by 41.2% to 413,384 shares valued at $67.74 million. Despite the sell-off, Repligen exceeded its Q earnings estimates, with revenue up 18.1% year-over-year and analysts maintaining a "Moderate Buy" consensus rating with a target price of $170.93. Institutional investors collectively own a substantial 97.64% of the company's stock.
MAR 12·openPR.com▲
Biological Product IgG Purification Medium Market Is Going to Boom | Repligen Corporation • Agilent Technologies
The Biological Product IgG Purification Medium Market is projected to see substantial growth from 2026 to 2033, driven by increasing demand and innovation. A new report by Coherent Market Insights provides a deep dive into market trends, competitive landscapes, and growth opportunities, offering essential insights for industry leaders. Key players include Thermo Fisher Scientific, Merck KGaA, and Repligen Corporation.
